ARDS – Medxy AI

Inflammatory Subphenotypes in COVID-19 ARDS Exhibit High Temporal Stability: Insights from the ICAR Trial

By MedXY 12/27/2025

A reanalysis of the ICAR trial reveals that ARDS inflammatory subphenotypes remain remarkably stable over 28 days. The hyperinflammatory profile is linked to higher mortality and distinct biomarkers, with Bayesian modeling showing minimal transitions between phenotypes over time.

Critical Care news Respiratory

Dynamic Phenotyping in ARDS: AI-Driven Insights Reveal Why Corticosteroid Benefits Depend on Inflammatory State

By MedXY 12/27/2025

A groundbreaking study utilizing an AI classifier demonstrates that ARDS inflammatory phenotypes are dynamic and dictate corticosteroid efficacy. While hyperinflammatory patients benefit from steroids, hypoinflammatory patients face increased mortality, necessitating real-time phenotypic monitoring to optimize critical care interventions.

Critical Care news Oncology

Survival in Cancer Patients with ARDS: The YELENNA Study Challenges ECMO Utility in Severe Cases

By MedXY 12/27/2025

The YELENNA prospective study reveals a 73.2% 90-day mortality rate for cancer patients with ARDS. Crucially, venovenous ECMO provided no survival benefit in severe cases, prompting a re-evaluation of current clinical guidelines and goals-of-care discussions for this high-risk population.

Critical Care news Respiratory

Fewer Post‑Traumatic ARDS Cases but Rising Mortality: A 2007–2019 NTDB Cohort Analysis

By MedXY 12/09/2025

A 2007–2019 National Trauma Data Bank analysis found ARDS incidence among ventilated trauma patients fell substantially, yet ARDS remained independently associated with increased 30‑day mortality and crude ARDS mortality rose to nearly 30%. Modifiable patient- and center-level factors deserve attention.

Critical Care news Respiratory

Prolonged Prone Positioning in ARDS: Current Evidence Is Inconclusive — No Clear Mortality or Safety Benefit

By MedXY 11/11/2025

A systematic review and meta-analysis found no clear mortality, oxygenation, or safety benefit for prolonged prone positioning (≥24 h) in ARDS; evidence is low to very low certainty and does not support routine use outside clinical trials.

Critical Care news Respiratory

Circulating Endothelial Transcriptomic Signatures Predict Worse Outcomes in COVID-19, Respiratory Failure and ARDS

By MedXY 11/07/2025

Transcriptomic deconvolution of blood identifies elevated circulating endothelial signatures (ECS%) that associate with higher 28‑day mortality and worse respiratory trajectories in pediatric respiratory failure and adults hospitalized with COVID‑19.

Critical Care news Respiratory

Trunk Inclination Changes Worsen Compliance and Raise PaCO2 in Obese ARDS Patients: Clinical Implications from a Seven-Study Pooled Analysis

By MedXY 11/07/2025

A secondary analysis of 159 mechanically ventilated ARDS patients shows that increasing trunk inclination reduces respiratory system, lung, and chest wall compliance—especially in patients with obesity—and is associated with increased PaCO2 only in the obese subgroup.

Critical Care news Respiratory

Inhaled PEG‑Adrenomedullin in ARDS: Safe but Ineffective — Phase 2 RCT Stopped for Futility

By MedXY 11/07/2025

A multicentre randomized Phase 2a/b trial found inhaled pegylated adrenomedullin (PEG‑ADM) well tolerated in ventilated ARDS patients but without improvement in ventilator‑free survival or a composite clinical utility index; the study was stopped early for futility.